Neuropeptide-dopamine interactions. III. Cyclo(His-Pro) and persistence of dopaminergic supersensitivity on withdrawal from one year continuous neuroleptic treatment.
When rats are given dopaminergic antagonists (neuroleptics) continuously for several days behavioral supersensitivity to dopaminergic agonists results. This supersensitivity, however, declines rapidly on neuroleptic withdrawal. The data presented here, however, are the first to show that the supersensitivity persists for a longer duration (greater than 100 days) if the neuroleptic is administered continuously for 1 year. Oral administration of 0.76 +/- 0.13 mg/kg/day cyclo(His-Pro), a peptide exhibiting dopaminergic agonist-like properties, during neuroleptic withdrawal did not change the course of dopaminergic supersensitivity reversal.
Prasad
C
C
Department of Medicine, Louisiana State University Medical Center, New Orleans 70112.
D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects*; D004298:Dopamine / Q000502:physiology*; D006220:Haloperidol / Q000494:pharmacology; D008297:Male; D009479:Neuropeptides / Q000502:physiology*; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D051381:Rats; D011919:Rats, Inbred Strains; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy*
D014150:Antipsychotic Agents; D009479:Neuropeptides; D010456:Peptides, Cyclic; D010879:Piperazines; D006220:Haloperidol; C015924:histidyl-proline diketopiperazine; D004298:Dopamine